

Curriculum Vitae  
**Steven Eugene Young, MD**  
**17 Winslow Drive**  
**Martinsville, NJ 08836**  
**908-927-8700**

**Current Position:**

Partner

**Office Address:**

Regional Cancer Care Associates LLC Somerset Division  
30 Rehill Ave., Ste. 2500, Somerville, NJ 08876  
Tel: 908-927-8700 \* Fax: 908-927-8713

908 Oak Tree Ave., Ste I & J, South Plainfield, NJ 07080  
Tel: 908-205-8403 \* Fax: 908-205-8407  
Email: [StevenYoungMD@gmail.com](mailto:StevenYoungMD@gmail.com)

**Birth date:**

November 8, 1964

**Birthplace:**

Brooklyn, NY

**Education:**

Jun 1981-Apr 1985:

BS Biology  
College of Science  
University of Santo Tomas  
Manila, Philippines

Jun 1985-Apr 1989:

Medical Degree  
Faculty of Medicine and Surgery  
University of Santo Tomas  
Manila, Philippines

**Postdoctoral Training:**

May 1989-Apr 1990:

Rotating Internship  
Santo Tomas University Hospital  
Manila, Philippines

SY 6/20/14

Jul 1991-Jun 1994

Internal Medicine Residency  
The Brooklyn Hospital Center  
Brooklyn, NY

Jul 1994-Jun 1997

Hematology/Oncology Fellowship  
Mount Sinai Hospital of New York  
New York, NY  
(Hematology Chief Fellow - 3<sup>rd</sup> Year)

Apr 1998-Jul 1998:

Bone Marrow Transplant Fellow  
Visiting Physician Program  
Fred Hutchinson Cancer Research Center  
Seattle, WA

**Positions:**

Jan 2013 - Present

Private Practice Regional Cancer Care Associates LLC  
Somerset Division

Nov 1998 - Dec 2012

Private Practice Somerset Hematology-Oncology Associates

Jan 2008 - Dec 2011

Chief of Oncology - Somerset Medical Center

**Certifications**

1997: American Board of Internal Medicine  
1998: American Board of Hematology  
1999: American Board of Medical Oncology

**Memberships:**

Member of American Society of Clinical Oncologists  
Member of American Society of Hematology

**Licensure:**

1990: Philippine Board of Medicine  
1994: New York  
1998: New Jersey #68062

**Clinical Trials Experience:** Pharmaceutical Sponsored Trials

As Principal Investigator:

Sy 6/20/14

Sept 2003 - Feb 2004	Ortho Biotech PR03-27-007: An Open-Label Pilot Study to Evaluate the Effects of Alternate Dosing of Procrit (Epoetin Alfa) in the Treatment of Patients With Cancer and Chemotherapy Induced Anemia (60,000 Units weekly for four weeks followed by 60,000 units every two weeks).
Nov 2006 - present	Pfizer A8501006: A Randomized Phase 2 Trial of Erlotinib With or Without PF-3512676 For The Treatment of Patients With Advanced EGFR-Positive Non-Small Cell Lung Cancer After failure Of At Least One Prior Chemotherapy Regimen
Nov 2007 - present	Millennium C05009: Randomized, Phase 3B Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE® (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan, and Prednisone (VMP)
Oct 2007 - present	Novartis CZOL446EUS129: Bone Marker Directed Dosing of ZOMETA (zoledronic acid) for the Prevention of Skeletal Complications in Patients with Advanced Multiple Myeloma
Feb 2008 - present	Wyeth 3160A4-3000-WW: A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Nov 2008 - present	Novartis CST1571A2402: A Worldwide, Observational Registry collecting Longitudinal data on the Management of Chronic Myelogenous Leukemia (CML) patients (The WORLD CML Registry) in routine practice
Jul 2008 - present	Novartis CST1571BUS227: reGISTry
Aug 2009 - present	Incyte INCB18424-351: A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF), or Post-Essential Thrombocytopenia-Myelofibrosis (PET-MF)

Sm 6/20/14

May 2010 - present	Novartis CLBH589DUS71: A Phase II, Multi-center, Single-arm, Open label Study of Panobinostat in combination with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma
May 2010 - Mar 2011	Cephalon C18083/2048: A Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
Nov 2010 - present	A Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to Intolerant of Hydroxyurea : JAK Inhibitor INC424 tablets versus Best Available Care (The RESPONSE Trial)
Feb 2011 - present	A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil As First-Line Therapy for Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Nov 2011 - present	An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocytopenia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of $50 \times 10^9/L$ to $100 \times 10^9/L$
Jun 2011 - present	A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy
June 2013 - present	Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
<u>As Sub-Investigator:</u> March 2002 - May 2005	Ligand L1069-48: Randomized, Phase 3 Trial Comparing Targretin Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy Naïve Patients with Advanced Non Small Cell Lung Cancer

Smy 6/20/14

Jul 2003 - Feb 2004	Open-Label Study of Alimta® (pemetrexed) Alone or in Combination with Cisplatin for Patients with Malignant Mesothelioma
Aug 2005 - Dec 2006	Amgen 20040262: A Study to Assess the Impact of Once per Cycle Correction and Maintenance Dosing of Darbepoetin Alfa in Subjects with Non-Myeloid Malignancies with Anemia Due to Chemotherapy
April 2004 - Aug 2005	Amgen 20030206: A Study to Evaluate the Effectiveness of Aranesp® at 300 mcg on Clinical Outcomes in Cancer Patients with Anemia Due to Chemotherapy
Oct 2004 - Jan 2006	Amgen 20020715: Chemotherapy Administered Every 2 Weeks With or Without A Single Injection of Pegfilgrastim As First Or Second Line Treatment in Subjects With Locally Advanced Or Metastatic Colon Cancer
April 2005 - Nov 2006	Amgen 20040249: A Randomized, Open-Label, Controlled Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects with Metastatic Colorectal Cancer
Nov 2006 - present	Amgen 20060141: A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as a Second-line Treatment in Subjects with Metastatic Colorectal Cancer
Nov 2007 - Nov 2008	Eisai E7389-G000-301: A Phase III Open-Label, Randomized Two-Parallel-Arm Multi-Center Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes
March 2006 - present	Novartis CZOL446E2352: A prospective, randomized, double-blind, stratified, multi-center, 2-arm trial of the continued efficacy and safety of Zometa® (every 4 weeks vs. every 12 weeks) in patients with documented bone metastases from breast cancer
Sept 2009 - present	Millennium C05012: A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of Velcade® (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without

Smy 6/20/2014

Doxorubicin followed by Rituximab Maintenance in Patients with  
Relapsed Follicular Lymphoma

Dec 2011 - present

A Phase 3 Open-Label Randomized Study to Compare the  
Efficacy and Safety of Rituximab Plus Lanelidomide (CC-5013)  
Versus Rituximab Plus Chemotherapy Followed by Rituximab in  
Subjects with Previously Untreated Follicular Lymphoma

Sm 6/20/2014